Dalack GW - Search Results

1

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature.

Dalack GW, Meador-Woodruff JH. Dalack GW, et al. Schizophr Res. 1996 Nov 15;22(2):133-41. doi: 10.1016/s0920-9964(96)80441-5. Schizophr Res. 1996. PMID: 8958597 Review.

2

Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders.

Diwan A, Castine M, Pomerleau CS, Meador-Woodruff JH, Dalack GW. Diwan A, et al. Among authors: dalack gw. Schizophr Res. 1998 Sep 7;33(1-2):113-8. doi: 10.1016/s0920-9964(98)00045-0. Schizophr Res. 1998. PMID: 9783351

3

Tardive dyskinesia, clozapine, and treatment response.

Dalack GW, Becks L, Meador-Woodruff JH. Dalack GW, et al. Prog Neuropsychopharmacol Biol Psychiatry. 1998 May;22(4):567-73. doi: 10.1016/s0278-5846(98)00026-8. Prog Neuropsychopharmacol Biol Psychiatry. 1998. PMID: 9682273

4

Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia.

Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. Dalack GW, et al. Neuropsychopharmacology. 1999 Aug;21(2):195-202. doi: 10.1016/S0893-133X(98)00121-3. Neuropsychopharmacology. 1999. PMID: 10432467 Clinical Trial.

5

Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Dalack GW, Healy DJ, Meador-Woodruff JH. Dalack GW, et al. Am J Psychiatry. 1998 Nov;155(11):1490-501. doi: 10.1176/ajp.155.11.1490. Am J Psychiatry. 1998. PMID: 9812108 Review.

6

The role of life events in onset and recurrent episodes of schizophrenia and schizoaffective disorder.

Castine MR, Meador-Woodruff JH, Dalack GW. Castine MR, et al. Among authors: dalack gw. J Psychiatr Res. 1998 Sep-Oct;32(5):283-8. doi: 10.1016/S0022-3956(98)00017-X. J Psychiatr Res. 1998. PMID: 9789206

7

Acute feasibility and safety of a smoking reduction strategy for smokers with schizophrenia.

Dalack GW, Meador-Woodruff JH. Dalack GW, et al. Nicotine Tob Res. 1999 Mar;1(1):53-7. doi: 10.1080/14622299050011151. Nicotine Tob Res. 1999. PMID: 11072388 Clinical Trial.

8

Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disorders.

Grove T, Taylor S, Dalack G, Ellingrod V. Grove T, et al. Schizophr Res. 2015 May;164(1-3):115-21. doi: 10.1016/j.schres.2015.02.006. Epub 2015 Feb 23. Schizophr Res. 2015. PMID: 25728832 Free PMC article.

9

Dietary, lifestyle and pharmacogenetic factors associated with arteriole endothelial-dependent vasodilatation in schizophrenia patients treated with atypical antipsychotics (AAPs).

Ellingrod VL, Taylor SF, Brook RD, Evans SJ, Zöllner SK, Grove TB, Gardner KM, Bly MJ, Pop-Busui R, Dalack G. Ellingrod VL, et al. Schizophr Res. 2011 Aug;130(1-3):20-6. doi: 10.1016/j.schres.2011.03.031. Epub 2011 Apr 19. Schizophr Res. 2011. PMID: 21504842 Free PMC article.

10

Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics.

Ellingrod VL, Taylor SF, Dalack G, Grove TB, Bly MJ, Brook RD, Zöllner SK, Pop-Busui R. Ellingrod VL, et al. J Clin Psychopharmacol. 2012 Apr;32(2):261-5. doi: 10.1097/JCP.0b013e3182485888. J Clin Psychopharmacol. 2012. PMID: 22370993 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results